A woman navigating perimenopause, fertility challenges, or postpartum recovery in the Netherlands might see a general practitioner, a gynecologist, and a specialist for each distinct issue. The care is often fragmented, the wait times long, and the burden of navigating the system falls squarely on the patient. Flouria Health, a digital clinic founded in Amsterdam in 2024, is betting that a single, accessible online platform can provide a better path for the full spectrum of women's hormonal health.
In October 2026, the company announced it had reached €1.5 million in total funding with an investment from Dutch health-tech investor Healthy.Capital [Flouria Health, October 2026]. The capital is earmarked for growth in the Netherlands and expansion into other European markets. Since launching its direct-to-consumer proposition in October 2025, Flouria reports it has served more than 1,000 women [Femtech Insider, October 2026].
The full-lifecycle wedge
Flouria's core bet is on continuity of care. Rather than focusing on a single condition, its platform offers online specialist consultations and personalized care plans across several interconnected life stages, including perimenopause, fertility, PCOS, and postpartum recovery [PERPLEXITY SONAR PRO BRIEF]. The company positions this integrated approach as a wedge against a healthcare system where women are often shuffled between disconnected specialists.
Treatment can include hormone replacement therapy (HRT) prescriptions for perimenopause, structured support for fertility journeys, and guidance for postpartum recovery, all delivered through a unified digital interface [Flouria Health, retrieved 2026]. The model combines clinical consultations with at-home testing and digital tracking tools, aiming to create a cohesive care trajectory that adapts as a patient's needs evolve.
A founding team forged by personal experience
The company's three co-founders bring a mix of operational, technical, and commercial experience, but they also share a powerful, personal driver. Each was motivated by direct encounters with gaps in women's healthcare, including experiences with infertility, pregnancy loss, postpartum care, and early menopause [PERPLEXITY SONAR PRO BRIEF].
| Founder | Role | Background & Note |
|---|---|---|
| Jeanine van Munster | Co-Founder & CEO | Investor and strategy consultant with a finance background; personal experience with early perimenopause and fertility [PERPLEXITY SONAR PRO BRIEF]. |
| Vlatko Stojkovski | Co-Founder & CTO | Second-time health-tech founder responsible for building Flouria's technology in-house [PERPLEXITY SONAR PRO BRIEF]. |
| Anna Christie | Co-Founder & CCO | Commercial sales and marketing background; hosts a women's health podcast; personal experience with fertility and postpartum care [PERPLEXITY SONAR PRO BRIEF]. |
The company has also built out its clinical leadership, naming Lotte van Dijk and Jolijn Huisman as medical leads [PERPLEXITY SONAR PRO BRIEF]. This blend of lived experience and professional expertise is central to the company's narrative, framing its mission as both a business opportunity and a personal imperative.
Traction and the path to scale
Flouria's reported traction of over 1,000 patients in its first year is a key early signal. It suggests there is consumer demand in the Netherlands for a dedicated, digital-first approach to hormonal health that transcends single-issue clinics. The company operates on a direct-to-consumer model, which allows for rapid patient acquisition and feedback but also places the full burden of customer acquisition cost on the startup.
The recent €1.5 million in funding provides runway to refine this model. The stated goal is twofold: deepen its presence in the Dutch market and begin a careful expansion into other European countries [Startup.eu, October 2026]. Success in new markets will depend on navigating different regulatory frameworks for telemedicine and prescription delivery, as well as adapting to local healthcare cultures.
The regulatory and competitive landscape
While the public record does not name direct competitors, Flouria is entering a crowded and complex segment. The digital health space for women is active, with numerous startups targeting specific niches like fertility tracking, menopause support, or PCOS management. Flouria's broad, lifecycle-wide approach is its differentiator, but it also means competing with more established, single-focus players on multiple fronts simultaneously.
The regulatory context is equally critical. As a digital clinic prescribing medications like HRT, Flouria must maintain rigorous clinical governance and operate within the strict telemedicine guidelines of each country it enters. The absence of a named pharmacy or laboratory partner in public materials is a point to watch, as smooth integration with these services is often what separates a convenient app from a comprehensive care provider.
What the standard of care looks like today
For the patient population Flouria serves,women dealing with perimenopause, fertility issues, PCOS, or postpartum concerns,the current standard of care is often a patchwork. It typically begins with a visit to a time-pressed primary care doctor, followed by a referral to a specialist with a potentially long wait time. Treatment plans are rarely coordinated between different doctors, and vital education about hormonal changes is frequently lacking. This disjointed process leaves many patients feeling dismissed and forced to become their own care coordinators. Flouria's bet is that by centralizing specialist knowledge and care coordination into a single, accessible digital clinic, it can offer a more humane, effective, and continuous alternative.
The next twelve months will be about proving that this integrated model can scale beyond its initial 1,000-patient cohort. Key milestones will include demonstrating sustainable patient growth in the Netherlands, announcing its first expansion market, and potentially forging the strategic partnerships with pharmacies or insurers that could lower patient costs and solidify its clinical infrastructure. For now, the company has secured the capital and demonstrated the early patient demand to make its case.
Sources
- [Flouria Health, October 2026] Flouria adds Healthy.Capital to €1.5M funding | https://flouria.health/press/funding-announcement
- [Femtech Insider, October 2026] Flouria Health Raises Funding to Scale Women’s Hormonal Health Platform | https://femtechinsider.com/flouria-health-raises-funding-to-scale-womens-hormonal-health-platform/
- [Startup.eu, October 2026] Amsterdam-based Flouria Health reaches €1.5M in funding with Healthy.Capital investment to expand women’s hormonal health clinic across Europe | https://www.startup.eu/investments/flouria-health-1-5-m-10-2026
- [PERPLEXITY SONAR PRO BRIEF] Web-grounded company brief
- [Flouria Health, retrieved 2026] Company website | https://flouria.health/